CRISPR-Cas9

[Rheumatology] OPG-XL was studied by human induced pluripotent stem cells expressing OPG-XL and two isogenic CRISPR/Cas9-corrected controls in cartilage and bone organoids.

[Nature Communications] Scientists used a “two cell type” whole genome CRISPR-Cas9 screening system to discover key regulators of tumor sensitivity and resistance to natural killer cell-mediated cytotoxicity in human glioblastoma stem cells.

[Neuro-Oncology] Researchers screened a library of drugs either FDA-approved or in clinical trial using a library of patient-derived H3K27M-mutant diffuse midline glioma cell lines with cell viability as the outcome.

[Molecular Neurodegeneration] Investigators performed a fluorescent cell sorting based genome-wide CRISPR-Cas9 screen in αS biosensors. αS and TDP-43 seeding activity under varied conditions was assessed using FRET/Flow biosensor cells or immunofluorescence for phosphorylated αS or TDP-43 in primary cultured neurons.

[Cardiovascular Research] The authors derived patient hiPSC-CMs carrying compound mutations in the adult SCN5A exon 6B and exon 4. Electrophysiological properties of patient hiPSC-CMs in monolayer were not altered by the exon 6B mutation compared to isogenic controls since it was not expressed.

[Signal Transduction and Targeted Therapy] Via an unbiased genome-wide CRISPR/Cas9 screening, scientists identified loss of NOXA, a B-cell lymphoma 2 family protein in B cell malignancies, as a pivotal regulator of resistance to CAR T cell therapy by impairing apoptosis of tumor cells both in vitro and in vivo.